業務
貨幣單位:EUR
2025/Q3
名稱營收比例
Research and development of PRAME-directed immunotherapies for the treatment of cancer518.7萬100.00%
地區
貨幣單位:EUR
2024/FY
名稱營收比例
BMS, United States7,809.9萬50.12%
Moderna, United States6,278.5萬40.29%
Genmab, Denmark1,495.1萬9.59%